BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M, Kiani J. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer. Front Immunol 2020;11:2062. [PMID: 33117331 DOI: 10.3389/fimmu.2020.02062] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Jain S, Sheth RA. Modulating the tumor immune microenvironment with locoregional image-guided interventions. Front Immunol 2022;13:1057597. [PMID: 36685505 DOI: 10.3389/fimmu.2022.1057597] [Reference Citation Analysis]
2 Camperi J, Console G, Zheng L, Stephens N, Montti M, Roper B, Zheng M, Moshref M, Dagdas Y, Holder P, Stella C. Comprehensive UHPLC- and CE-based methods for engineered Cas9 characterization. Talanta 2023;252:123780. [DOI: 10.1016/j.talanta.2022.123780] [Reference Citation Analysis]
3 Rodrigo S, Senasinghe K, Quazi S. Molecular and therapeutic effect of CRISPR in treating cancer. Med Oncol 2023;40:81. [PMID: 36650384 DOI: 10.1007/s12032-022-01930-6] [Reference Citation Analysis]
4 Hosseini SA, Salehifard Jouneghani A, Ghatrehsamani M, Yaghoobi H, Elahian F, Mirzaei SA. CRISPR/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy. Int J Biol Macromol 2022;223:732-54. [PMID: 36372102 DOI: 10.1016/j.ijbiomac.2022.11.018] [Reference Citation Analysis]
5 Ye Q, Guo NL. Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. Cells 2022;12. [PMID: 36611894 DOI: 10.3390/cells12010101] [Reference Citation Analysis]
6 Tsai H, Pietrobon V, Peng M, Wang S, Zhao L, Marincola FM, Cai Q. Current strategies employed in the manipulation of gene expression for clinical purposes. J Transl Med 2022;20:535. [DOI: 10.1186/s12967-022-03747-3] [Reference Citation Analysis]
7 Hayes BH, Zhu H, Andrechak JC, Discher DE. Titrating CD47 by mismatch CRISPRi reveals incomplete repression can eliminate IgG-opsonized tumors but CD47 heterogeneity limits induction of anti-tumor IgG.. [DOI: 10.1101/2022.09.27.509740] [Reference Citation Analysis]
8 Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther 2022;7:331. [PMID: 36123348 DOI: 10.1038/s41392-022-01136-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Karn V, Sandhya S, Hsu W, Parashar D, Singh HN, Jha NK, Gupta S, Dubey NK, Kumar S. CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope. Cancer Cell Int 2022;22:234. [PMID: 35879772 DOI: 10.1186/s12935-022-02654-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bhattacharjee R, Das Roy L, Choudhury A. Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics. Discov Oncol 2022;13:45. [PMID: 35674844 DOI: 10.1007/s12672-022-00509-x] [Reference Citation Analysis]
11 Sansbury BM, Hewes AM, Tharp OM, Masciarelli SB, Kaouser S, Kmiec EB. Homology directed correction, a new pathway model for point mutation repair catalyzed by CRISPR-Cas. Sci Rep 2022;12:8132. [PMID: 35581233 DOI: 10.1038/s41598-022-11808-2] [Reference Citation Analysis]
12 Khatami F, Aghamir ZS, Jahanshahi F, Feiz-Abadi SA, Birang F, Khoshchehreh M, Namazi Shabestari A, Aghamir SMK. The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer. Iran J Biotechnol 2022;20:e3094. [PMID: 36337063 DOI: 10.30498/ijb.2022.294933.3094] [Reference Citation Analysis]
13 Balon K, Sheriff A, Jacków J, Łaczmański Ł. Targeting Cancer with CRISPR/Cas9-Based Therapy. Int J Mol Sci 2022;23:573. [PMID: 35008996 DOI: 10.3390/ijms23010573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Hariprabu KNG, Sathya M, Vimalraj S. CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis. Int J Biol Macromol 2021;192:913-30. [PMID: 34655593 DOI: 10.1016/j.ijbiomac.2021.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Qiu M, Li P. CRISPR/Cas-based Diagnostics and Gene Therapy. BIO Integration 2021;2:121-9. [DOI: 10.15212/bioi-2020-0048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Murty T, Mackall CL. Gene editing to enhance the efficacy of cancer cell therapies. Mol Ther 2021;29:3153-62. [PMID: 34673274 DOI: 10.1016/j.ymthe.2021.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Bakken V. CRISPR-Cas: Aktuelle og mulige anvendelser i odontologi. Tidende 2021;132. [DOI: 10.56373/2021-10-5] [Reference Citation Analysis]
19 Cook J, Acosta-Medina AA, Peng KW, Lacy M, Russell S. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. Cancer Treat Res Commun 2021;29:100473. [PMID: 34673439 DOI: 10.1016/j.ctarc.2021.100473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Xiao W, Zhou Q, Wen X, Wang R, Liu R, Wang T, Shi J, Hu Y, Hou J. Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy. Front Pharmacol 2021;12:702360. [PMID: 34603017 DOI: 10.3389/fphar.2021.702360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev 2021;176:113891. [PMID: 34324887 DOI: 10.1016/j.addr.2021.113891] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
22 Koniali L, Lederer CW, Kleanthous M. Therapy Development by Genome Editing of Hematopoietic Stem Cells. Cells 2021;10:1492. [PMID: 34198536 DOI: 10.3390/cells10061492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Morvan MG, Teque F, Ye L, Moreno ME, Wang J, VandenBerg S, Stoddart CA, Kan YW, Levy JA. Genetically edited CD34+ cells derived from human iPS cells in vivo but not in vitro engraft and differentiate into HIV-resistant cells. Proc Natl Acad Sci U S A 2021;118:e2102404118. [PMID: 33975958 DOI: 10.1073/pnas.2102404118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Deepak Singh D, Han I, Choi EH, Yadav DK. CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. Comput Struct Biotechnol J 2021;19:2384-97. [PMID: 34025931 DOI: 10.1016/j.csbj.2021.04.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
25 Di Fiore R, Suleiman S, Ellul B, O'Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimaș-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers (Basel) 2021;13:493. [PMID: 33514073 DOI: 10.3390/cancers13030493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
26 Rodgers T, Muzzio N, Watson C, Romero G. Stabilization of Poly (β-Amino Ester) Nanoparticles for the Efficient Intracellular Delivery of PiggyBac Transposon. Bioengineering (Basel) 2021;8:16. [PMID: 33498466 DOI: 10.3390/bioengineering8020016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]